Siemens Healthineers at AACC 2019
Experience our newest innovations in Booth #1039

Siemens Healthineers at AACC 2019
Siemens Healthineers at AACC 2019
 
Follow Us on Social Media

Outcomes that matter. For each patient. For every provider.

There are 7.2 billion people on Earth, and each one deserves accurate diagnostic results. Whether you need the highest immunoassay testing throughput,¹ a handheld blood gas analyzer that can deliver results in less than one minute,² a true high-sensitivity troponin I assay, one of the largest ranges of molecular assays for infectious disease testing,³ or digital and AI innovations to keep you at the forefront, Siemens Healthineers offers proven, customized diagnostic solutions that are transforming care delivery.

Because each healthcare challenge is unique—just like the patients you serve.

Join us in Booth #1039 at the 71st AACC Annual Scientific Meeting & Clinical Lab Expo
Sunday, August 4–Thursday, August 8, 2019 | Anaheim, CA

Educational Highlights

Industry-sponsored Workshops

Pre-registration is not required for the following sponsored workshops. Workshops are open to all congress attendees on a first-come, first-served basis.


Improving Outcomes with Effective Chronic-Disease Management at the Point-of-Care
Tuesday, August 6 | 10:15—11:15 a.m. | Exhibit Hall | Theater 1

Download calendar blocker 7.5 kB

Summary
With increases in quality standards and patient volume, and continuing reduction of resources, this panel includes lively discussions of challenges and best practices in hospital chronic-disease patient management via point-of-care solutions.

Learning Objectives

  • Identify current challenges in chronic-disease patient management for hospital systems.
  • Map the value of point-of-care solutions to address chronic-disease patient management and increase staff efficiency.
  • Understand how POC connectivity enables data collection and compliance.

Chair/moderator: Connie Mardis, Siemens Healthineers

Speakers
Joe Paul Gallo, RN, WHNP BC-E, MSN Ed, CST
Director of Chronic Disease Management and Communicable Disease, Denton County Public Health, TX, USA

Leslie Lam, MBBS (Melbourne), DABCC, MAACB, FACB, FAMS (Pathology)
Director of Chemical Pathology, Senior Consultant, Laboratory Medicine, Ng Teng Fong General Hospital, Singapore

Felicity Dempsey
Founder and Head of POCT Consultancy Services, Dublin, Ireland


Implementation of High-Sensitivity Troponin I Starts in the Laboratory
Tuesday, August 6 | 12:45—1:45 p.m. | Exhibit Hall | Theater 1

Download calendar blocker 7.2 kB

Summary
High-sensitivity cardiac troponin assays can play a critical role in the expedited diagnosis of acute myocardial infarction. Successful implementation of high-sensitivity troponin I starts in the laboratory. Learn about the keys to a successful transition, along with the latest HIGH-US clinical trial data documenting the performance of the Atellica® IM High-Sensitivity Troponin I (TnIH) Assay.

Learning Objectives

  • Understand the importance of high-sensitivity troponin I.
  • Learn how to successfully implement high-sensitivity troponin I in your institution.
  • Learn about the robust HIGH-US clinical trial data that demonstrates the performance of the Atellica IM TnIH Assay.

Chair/moderator: Melanie Pollan, Siemens Healthineers

Speakers
Alan Wu, PhD, DABCC, FACB
Chief, Clinical Chemistry and Toxicology Laboratories
Zuckerberg San Francisco General Hospital and Trauma Center, San Francisco, CA

Robert H. Christenson, PhD, DABCC, FACB
Professor, Department of Pathology
University of Maryland, School of Medicine, Baltimore, MD
 


Managing Patient Pathways and Improving Outcomes in NAFLD and NASH*
Tuesday, August 6 | 1:45—2:45 p.m. | Exhibit Hall | Theater 1

Download calendar blocker 8.8 kB

Summary
Nonalcoholic fatty liver disease (NAFLD), in which fat deposits in the liver, affects over 1 billion people globally1 and is projected to become the leading cause of liver-related mortality within 20 years.2 Learn about current testing options that address this unmet clinical need.

Learning Objectives

  • Understand the epidemiology of NAFLD and nonalcoholic steatohepatitis (NASH).
  • Review practice guidelines and challenges in disease management.
  • Learn about therapies and how noninvasive blood tests can help manage the NAFLD pathway.

Chair/moderator: Andrew Beard, Siemens Clinical Laboratory

Speakers
Zobair M. Younossi, MD, MPH, FACP, FACG, AGAF
Chairman, Department of Medicine, Inova Fairfax Medical Campus
Professor of Medicine, Virginia Commonwealth University, Inova Campus
Affiliate Professor of Biomedical Sciences at George Mason University, Fairfax, VA

Arun J. Sanyal, MD
Professor, Department of Internal Medicine
Division of Gastroenterology, Hepatology and Nutrition
Virginia Commonwealth University, Richmond, VA
 

1. Munteanu MA, Nagy GA, Mircea PA. Current management of NAFLD. Clujul Med. 2016;89(1):19-23. doi:10.15386/cjmed-539
2. Ray K. NAFLD–the next global epidemic. Nat Rev Gastroenterol Hepatol. 2013;10:621. doi: 10.1038/nrgastro.2013.197
* Presented by Siemens Clinical Laboratory


Free Light Chain Testing in Diagnosis and Monitoring of Multiple Myeloma by N Latex FLC kappa and lambda Assays
Wednesday, August 7 | 3:30—4:30 p.m. | Exhibit Hall | Theater 1

Download calendar blocker 6.7 kB

Summary
Free light chain (FLC) kappa and lambda testing was incorporated in the diagnostic criteria for multiple myeloma requiring therapy by the International Myeloma Working Group in 2014. The test is also used to monitor response and relapse in light chain multiple myeloma (LCMM) and is frequently applied as an additional marker in multiple myeloma (MM) monitoring, together with serum and urine electrophoresis, immunofixation, and quantification of the M-protein. Data collected in a multicentric study comparing the N Latex FLC kappa and lambda method versus the FREELITE kappa and lambda method for diagnosis and monitoring of multiple myeloma patients and a comparison of both FLC methods versus clinical status will be presented.

Learning Objectives

  • Describe the FLC kappa and lambda testing application for diagnosis and monitoring of multiple myeloma.
  • Appraise the performance of N Latex FLC kappa and lambda assays compared to competitor methods.
  • Review the clinical performance of N Latex FLC kappa and lambda assays for diagnosis and monitoring of multiple myeloma.

Chair/moderator: Dr. Claus Prümper, Siemens Healthineers
Speaker:
Maria Alice V. Willrich, PhD
Assistant Professor of Laboratory Medicine and Pathology - Mayo Clinic College of Medicine and Science
Consultant - Division of Clinical Biochemistry & Immunology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN


Joint Industry-sponsored Workshop

Pre-registration is required. Limited seating. Early arrival is recommended. A continental breakfast will be included.

The Fourth Universal Definition of Myocardial Infarction in Conjunction with the Clinical Laboratory Practice Recommendations for the Use of High Sensitivity Cardiac Troponin in Acute Coronary Syndrome.
Wednesday, August 7, | 7:00—8:30 a.m. | Hilton Anaheim | California Ballroom C/D

Register now

Keynote Speakers:

Fred S. Apple, PhD, DABCC, FACSM
Allan Jaffe, MD
Richard Body, MB ChB, MRCSEd (A&E), FRCEM, PhD
Pete Kavsak, PhD, FCACB, FAACC, FCCS


Follow Us on Social Media

Get the latest news and updates before, during, and after EuroMedLab.


Compartilhe esta página:

Product availability may vary from country to country and is subject to varying regulatory requirements.